Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study C Bezzio, S Saibeni, A Variola, M Allocca, A Massari, V Gerardi, V Casini, ... Gut 69 (7), 1213-1217, 2020 | 351 | 2020 |
A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. R Pellicano, DG Ribaldone, S Fagoonee, M Astegiano, GM Saracco, ... Panminerva medica 58 (4), 304-317, 2016 | 137 | 2016 |
Irritable bowel syndrome: the clinical approach. A Adriani, DG Ribaldone, M Astegiano, M Durazzo, GM Saracco, ... Panminerva medica 60 (4), 213-222, 2018 | 133 | 2018 |
History of inflammatory bowel diseases GC Actis, R Pellicano, S Fagoonee, DG Ribaldone Journal of clinical medicine 8 (11), 1970, 2019 | 123 | 2019 |
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents A Ciancio, R Bosio, S Bo, M Pellegrini, M Sacco, E Vogliotti, G Fassio, ... Journal of medical virology 90 (2), 320-327, 2018 | 111 | 2018 |
Serum zonulin in patients with inflammatory bowel disease: a pilot study GP Caviglia, F Dughera, DG Ribaldone, C Rosso, ML Abate, R Pellicano, ... Minerva Medica 110, 95-100, 2019 | 99 | 2019 |
Bone Mineral Density at Diagnosis of Celiac Disease and after 1 Year of Gluten‐Free Diet S Pantaleoni, M Luchino, A Adriani, R Pellicano, D Stradella, ... The Scientific World Journal 2014 (1), 173082, 2014 | 80 | 2014 |
Adalimumab therapy improves intestinal dysbiosis in Crohn’s disease DG Ribaldone, GP Caviglia, A Abdulle, R Pellicano, MC Ditto, M Morino, ... Journal of Clinical Medicine 8 (10), 1646, 2019 | 67 | 2019 |
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis DG Ribaldone, R Pellicano, M Vernero, GP Caviglia, GM Saracco, ... Scandinavian Journal of Gastroenterology 54 (4), 407-413, 2019 | 55 | 2019 |
Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease G Privitera, S Onali, D Pugliese, S Renna, E Savarino, A Viola, ... Journal of Crohn's and Colitis 15 (2), 335-339, 2021 | 53 | 2021 |
The usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study M Vernero, F De Blasio, DG Ribaldone, E Bugianesi, R Pellicano, ... Journal of clinical medicine 9 (12), 3941, 2020 | 50 | 2020 |
Physiopathology of intestinal barrier and the role of zonulin GP Caviglia, C Rosso, DG Ribaldone, F Dughera, S Fagoonee, ... Minerva biotecnologica 31 (3), 83-92, 2019 | 50 | 2019 |
P. 09.10 GLUCOSE BREATH TEST AND CROHN'S DISEASE: DIAGNOSIS OF SMALL INTESTINAL BACTERIAL OVERGROWTH AND EVALUATION OF THERAPEUTIC RESPONSE A Greco, GP Caviglia, DG Ribaldone, P Brignolo, S Reggiani, ... Digestive and Liver Disease 47 (S2), e177, 2015 | 48* | 2015 |
Fecal calprotectin: beyond intestinal organic diseases GP Caviglia, DG Ribaldone, C Rosso, GM Saracco, M Astegiano, ... Panminerva medica 60 (1), 29-34, 2018 | 43 | 2018 |
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis G Colombo, N Clemente, A Zito, C Bracci, FS Colombo, S Sangaletti, ... J Mol Med (Berl), 2020 | 42 | 2020 |
On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases GP Caviglia, C Rosso, F Stalla, M Rizzo, A Massano, ML Abate, A Olivero, ... Journal of Clinical Medicine 9 (3), 800, 2020 | 42 | 2020 |
Helicobacter pylori in celiac disease and in duodenal intraepithelial lymphocytosis: active protagonist or innocent bystander? D Simondi, DG Ribaldone, GA Bonagura, S Foi, N Sapone, M Garavagno, ... Clinics and research in hepatology and gastroenterology 39 (6), 740-745, 2015 | 42 | 2015 |
Oral manifestations of inflammatory bowel disease and the role of non-invasive surrogate markers of disease activity DG Ribaldone, S Brigo, M Mangia, GM Saracco, M Astegiano, R Pellicano Medicines 7 (6), 33, 2020 | 41 | 2020 |
Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients DG Ribaldone, S Fagoonee, M Astegiano, M Durazzo, A Morgando, ... Journal of Clinical Medicine 8 (2), 199, 2019 | 41 | 2019 |
Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series FM Phillips, B Verstockt, S Sebastian, DG Ribaldone, S Vavricka, ... J Crohns Colitis, 2020 | 40 | 2020 |